Trials / Completed
CompletedNCT00370513
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
Liver cancer is a good target for anti-angiogenic treatments such as pazopanib. The effect of pazopanib in patients with liver cancer are unknown. This study is designed to evaluate the safety, tolerability and best dose of pazopanib to be given to patient with liver cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pazopanib | Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR. |
Timeline
- Start date
- 2006-12-06
- Primary completion
- 2009-04-08
- Completion
- 2009-04-08
- First posted
- 2006-08-31
- Last updated
- 2017-11-17
Locations
3 sites across 3 countries: United States, Hong Kong, Taiwan
Source: ClinicalTrials.gov record NCT00370513. Inclusion in this directory is not an endorsement.